+161.7%
APLD vs MRNA
+153.9%
+7.8%
-76.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -17.8% | -2.2% | -15.6% | -17.6% |
| 7D | -28.1% | -12.7% | -15.4% | -27.1% |
| 30D | -45.2% | -20.7% | -24.6% | -44.0% |
| 3M | -59.9% | +46.3% | -106.2% | -61.3% |
| 6M | -70.9% | +305.2% | -376.2% | -78.4% |
| YTD | -53.1% | +561.2% | -614.4% | -71.3% |
| 1Y | -46.2% | +772.1% | -818.3% | -70.2% |
| 3Y | +161.7% | +147.0% | +14.8% | +101.0% |
| All | +161.7% | +153.9% | +7.8% | +101.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling